Oncology Institute (TOI) Director Mark L. Pacala Receives RSU Award

What Happened

• Mark L. Pacala, a director of Oncology Institute, Inc. (TOI), received a grant of 30,120 restricted stock units (RSUs) on July 27, 2026. The reported grant price was $0.00 per unit (total $0 reported at grant). The RSUs entitle him to one share of common stock per RSU upon settlement and vest in full on the date of the Issuer’s 2027 annual meeting of stockholders, subject to his continued service.

Key Details

• Transaction date: 2026-07-27; Form 4 filed: 2026-07-29 (timely filing).
• Transaction type/code: Award/Grant (A) — 30,120 RSUs @ $0.00 (reported acquisition value $0).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Each RSU converts to one share on settlement; full vesting on the 2027 annual meeting date, contingent on continued service.
• No indication of a sale, purchase for cash, or 10b5-1 plan; this is a standard equity compensation award.

Context

• RSU grants are a form of compensation and do not represent an immediate cash transaction or open-market purchase/sale. They generally align executive/director incentives with long-term shareholder value but do not by themselves indicate a buy or sell signal until vested shares are sold or otherwise transferred.